stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Shares outstanding
Protagonist Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $63.6M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $71.0M. Over the past ten years it has ranged from $252.0K (fiscal 2015) to $65.1M (fiscal 2024); the current reading is higher than 91% of that period. Protagonist Therapeutics, Inc. ranks 211th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $63.6M | (2.31%) |
| FY2024 | $65.1M | 14.65% |
| FY2023 | $56.8M | 15.74% |
| FY2022 | $49.0M | 5.87% |
| FY2021 | $46.3M | 34.67% |
| FY2020 | $34.4M | 32.84% |
| FY2019 | $25.9M | 15.78% |
| FY2018 | $22.4M | 26.39% |
| FY2017 | $17.7M | 172.15% |
| FY2016 | $6.5M | 2,480.16% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $71.0M | 0.73% |
| Mar 2026 | $70.5M | 10.88% |
| Dec 2025 | $63.6M | (0.31%) |
| Sep 2025 | $63.8M | 0.41% |
| 40 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| PTGX Protagonist Therapeutics, Inc. | $71.0M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement